Sartorius Stedim Biotech Confirms And Partially Refines Guidance For 2026

By Reuters News

- Sartorius Stedim Biotech STDM.PA:

  • SARTORIUS STEDIM BIOTECH 9M ADJUSTED EBITDA EUR 716 MILLION

  • SARTORIUS STEDIM BIOTECH 9M CASH FLOW FROM OPERATING ACTIVITIES EUR 497.6 MILLION

  • SARTORIUS STEDIM BIOTECH 9M ADJUSTED NET INCOME EUR 349.6 MILLION

  • SARTORIUS STEDIM BIOTECH 9M REVENUE EUR 2,289.2 MILLION

  • SARTORIUS STEDIM BIOTECH 9M ADJUSTED EPS EUR 3.59

  • SARTORIUS STEDIM BIOTECH 9M NET INCOME EUR 276.6 MILLION

  • SARTORIUS STEDIM BIOTECH 9M EPS EUR 2.84

  • MANAGEMENT CONFIRMS AND PARTIALLY REFINES GUIDANCE FOR 2026

  • CONFIRMS ITS SALES AND PROFITABILITY GUIDANCE FOR FY AND REFINES EXPECTED RATIO OF CAPITAL EXPENDITURE TO SALES REVENUE

  • OUTLOOK 2026: RATIO OF CAPITAL EXPENDITURE TO SALES REVENUE IS NOW EXPECTED TO BE AROUND 13 PERCENT

  • OUTLOOK 2026: RATIO OF NET DEBT TO UNDERLYING EBITDA SHOULD DECREASE TO SLIGHTLY ABOVE 2 (PY: 2.38)

Further company coverage: [STDM.PA]

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk